cyrilzakka/clinical-trials huggingface dataset:
Pediatric Pertussis in Ambulatory Settings

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

The whooping cough surveillance objectives are :

* to follow the duration of protection of the Ca vaccines in the context of modifications of the vaccine recommendations
* to describe the clinical characteristics of a population vaccinated with several boosters
* to adapt complementary examinations for diagnostic purposes (culture, PCR, serology) according to the evolution of scientific knowledge
* to monitor B. parapertussis infections
* to train laboratories with nasopharyngeal aspiration
* to monitor the evolution of the bacterial species All children aged 0-18 years, in whom the diagnosis of pertussis is mentioned and for which a biological check-up is requested, are included, except asymptomatic children with confirmed family case.

In case of suspected pertussis, real-time PCR and / or culture and / or (rarely) serology is / are still prescribed to the patient and / or his entourage.

Selected Pediatricians from the ACTIV group and the AFPA working in an outpatient clinic, located in different places in France, are participating in this network since 2001. The clinical evolution and the results of the examinations are transcribed on a case report form. The data are collected, firstly, during the visit where the diagnosis of whooping cough is suspected and a biological assessment requested (patient's medical history, clinical data, vaccination status and dates, as well as the search for a contaminated/contaminator) and secondly during the follow-up visit (results of the biological check-up and diagnosis, antibiotics potentially prescribed, and supplement data of the entourage, except in case of diagnosis of pertussis not retained).

All evaluations made by the pediatricians are regularly reviewed during meetings, and final diagnoses used are:

* biological pertussis
* epidemiological pertussis
* not evaluable
* lost of follow up
* no whooping cough

Eligibility Criteria:
Inclusion Criteria:

* All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested

Exclusion Criteria:

* children without symptoms with a household confirmed case
* cases for which the pertussis diagnosis was not suspected by the pediatrician
Measuring Electrical Resistance of Different Tissues on the Outer Surface of the Heart

This is a research study to evaluate the electrical properties of heart tissue. The purpose of this study is to determine the impedance (electrical resistance) of different tissues on the outer surface of the heart. This may be important for distinguishing scarred heart muscle from fat that can be seen on the surface of the heart. This information may eventually be utilized in patients that undergo a procedure (called catheter ablation) for the treatment of life-threatening heart rhythms. Investigators expect a detectable difference between the impedance of normal and infarcted myocardium (approximately 50 ohms).

The treatment of cardiac arrhythmias with endocardial catheter ablation has evolved rapidly over the past few decades. At the time of this writing, the ablation of almost all atrial and ventricular arrhythmias has been described in the literature. Multiple energy modalities (e.g. radiofrequency, cryotherapy) and approaches (e.g. retrograde aortic, transseptal puncture) have been described, yet ablation of some rhythms is not as successful as others.

The realization that ventricular tachycardia (VT) in the setting of Chagas Disease can originate in the epicardium has lead to the development of a percutaneous, transthoracic epicardial approach to mapping and ablation of this arrhythmia. This approach has now been applied to patients with VT in the setting of ischemic and nonischemic heart disease at many centers throughout the world. Traditional mapping technologies are utilized on the epicardium to define scarred heart tissue and locate the VT circuit.

It is well known that human hearts display a variable amount of fat overlying the epicardium. Not only is the coronary vasculature embedded in a layer of adipose tissue, but the rest of the heart may have areas of epicardial fat. As fat is an insulator and does not generate or easily conduct electrical activity, current mapping techniques may classify epicardial fat incorrectly as myocardial scar. This may have important effects on the ability to diagnose and treat arrhythmias with epicardial ablation.

Eligibility Criteria:
Inclusion Criteria:

* All adult patients undergoing elective cardiac surgery for coronary artery disease (with or without normal heart function) or valvular disease (with normal heart function) at the Hospital of the University of Pennsylvania under the direction of Y. Joseph Woo MD will be eligible.

Exclusion Criteria:

* Patients undergoing emergent surgery and patients with idiopathic cardiomyopathy, infiltrative cardiomyopathies and hypertrophic cardiomyopathies will be excluded.
Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.

This is a randomized control trial evaluating the effect of a novel mobile application-delivered pulmonary rehabilitation program in adult severe asthma patients. The intervention will include eight weeks of exercise videos that progress in difficulty, as well as asthma-specific educational content. The primary outcome measure is change in functional exercise capacity as measured by six-minute walk distance. Secondary outcome measures will include evaluation of overall feasibility, and change in CPET parameters such as VO2max. Change in asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) and PRAISE self-efficacy score will also be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years and older with a diagnosis of asthma by a respirologist. They must have severe disease defined by GINA severity classification. Participants must have access to a smartphone or internet browser to allow access to study content.

Exclusion Criteria:

* Exclusion criteria include comorbid cardiopulmonary or musculoskeletal conditions that may impact exercise tolerance in accordance with the American Thoracic Society CPET guidelines
Effect of PRP on the Therapy for Hair Growth

The purpose of study is to examine the advantage of PRP on hair loss and male pattern baldness. The investigators will inject PRP into the scalp regions where with little or no hair, and evaluate the effect and efficiency of PRP on human hair growth.

Hair loss is a disorder in which the hair undergoes aberration growth cycles and falls out from scalp. A number of factors like hormones, genetic factors, diet, endocrine abnormalities, systemic illnesses, drug intake, and hair shaft abnormalities may cause hair loss. Androgen alopecia or male pattern baldness is the most common cause of hair loss caused by progressive shortening of the anagen and increased number of hair follicles in telogen, which has a significant influence on psychological distress.

Except medical treatment and baldness surgery, a new interest in treating hair loss and baldness has been stimulated by using platelet plasma growth factors obtained from the patient's own platelet-rich plasma (PRP). PRP is a portion of plasma fraction of autologous blood having a high concentration of thrombocytes, and can be activated by Thrombin to release multiple growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), and transforming growth factor beta (TGF-β). PRP is known for the capacity to stimulate cell proliferation and differentiation. The action of platelet plasma growth factors on the development of hair follicles has already been established. PRP has also been shown to increase the yield of implanted follicular units during male baldness surgery.

Our study will focus on the advantage of PRP for the treatment of hair loss and male pattern baldness. PRP from autologous blood can be mixed with thrombin in appropriate ratio and inject into the regions on scalp which is interested. We will track and evaluate regularly the effect and efficiency of PRP on human hair growth.

Eligibility Criteria:
Inclusion Criteria:

* patient with hair loss/baldness
* age of 20-70 years old

Exclusion Criteria:

* patient with systemic disorder
* phyco
* patient with coagulation abnormality
* patient with inflammation
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias

This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.

This is a post-market, on-label study to understand the performance of the graft in the US.

Eligibility Criteria:
Inclusion Criteria:

* Subject must be willing and able to give written informed consent.
* Subject must be diagnosed with a ventral or incisional midline hernia.
* Mesh must be placed in the retro-rectus or intraperitoneal plane.
* Subject must be willing to undergo open hernia repair and be able to undergo all other study procedures as outlined in this protocol.

Exclusion Criteria:

* The use of surgical graft as a bridge repair.
* The subject has more than 4 prior recurrences.
* Subject has a contraindication for the placement of surgical graft.
* Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible.
* The study hernia repair requires more than a single piece mesh (including sufficient overlap beyond margins of the defect on all sides).
* Subject has intact permanent mesh adjacent to the current hernia to be repaired.
* Subject has peritonitis at the time of surgery.
* The subject is an active smoker within the last 2 weeks prior to surgery.
* Clinically significant Chronic Obstructive Pulmonary Disease or heart failure, defined as marked limitation in ability or inability to perform activities of daily living.
* Subject had chemotherapy within the last 12 months, is on or suspected to be placed on chemotherapy medications during any part of the study.
* Chronic steroid use (\>6 months) or immunosuppression drugs.
* Subject's body mass index (BMI) \>45 kg/m2.
* Subject has cirrhosis, and/or ascites.
* Subject has a defined collagen disorder.
* Known to be infected with human immunodeficiency virus (HIV).
* Subject has clinically significant (not based solely on creatinine levels) kidney disease that limits Activities of Daily Living, is on hemodialysis or peritoneal dialysis.
* Subject is American Society of Anesthesiology (ASA) Class 4 or 5.
* Subject has a life expectancy \< 2 years at the time of enrollment.
* Subject is pregnant, breastfeeding or planning on becoming pregnant during the course of the study.
* Subjects with known sensitivity to porcine products.
* Subjects with allergy, history of allergy or hypersensitivity to tetracyclines (including minocycline) or rifamycins (including rifampin).
* Subject has any condition in the opinion of the Investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.
Finding Wellness in the Pandemic

There is an immediate need for population-level intervention research to address the impacts of the coronavirus disease 2019 (COVID-19) pandemic and its containment measures on mental health and substance use (MHSU). While online programs are available to address these issues, they are often delivered in an asynchronous format with relatively low therapist or health coaching guidance. As highlighted by a recent systematic review, positive outcomes for online mental health programs are tied to the intensity of therapist or coaching guidance, which increases cost and reduces population access to more effective online options. A way to offset cost while maintaining effectiveness is to offer MHSU programs to groups online, rather than individually. In 2019, the investigators launched an RCT to test gender-stratified group interventions to address MHSU among community-based Indigenous and non-Indigenous adults in southern Alberta. The investigators implemented the interventions with more than 200 adults before the study was paused due to COVID-19.

The primary objective of this project is to adapt two existing mental health and substance use interventions and RCT for online delivery, COVID-19 impacts, and province-wide spread. The second objective is to test if an online group body-oriented intervention (trauma-sensitive yoga) that has been designed to increase awareness of physical sensations, is superior to an online group verbal narrative intervention (mental wellness talking circle), and to control group. The investigators theorize that the body-oriented intervention may offer the opportunity to reprogram automatic physiologic hyperarousal in response to COVID-19 triggers and increase positive body awareness, and mindful attention to the ways in which habitual self-protective behaviours like substance use may be impacting health. The third objective is to examine the impacts of the interventions on adults with pre-existing MHSU issues, and those with previous experiences that may make them more susceptible to MHSU problems during COVID-19. The investigators will track other supports the participants engage during the study and the perceived impacts of these supports on the outcomes with the goal of shedding light on how to best match COVID-19 related services to adults who need them the most.

Eligibility Criteria:
Inclusion Criteria:

* Women between 18-75 years living in Alberta, Canada
* Need to have reliable access to the internet, a device with a webcam for the next 2 months
* Need to self-identify that they are currently struggling with at least one of: stress eating, alcohol use, drug use, tobacco use, or gambling during the pandemic

Exclusion Criteria:

* Non-community dwelling
* Do not currently reside within Alberta, Canada
Single Rotary File System Versus Conventional Manual K-file in Pulpectomy of Primary Molars.

The sample size will be divided between two groups, Group A pulpectomy will be done using single rotary file in primary molars and group B pulpectomy will be done using manual K file system. follow up of the patients and clinical and radiographical success rates of cases will be seen.

Each patient will have access in the primary molar and pulpectomy procedure will be done according to inclusion and exclusion criteria , the patients will be divided according to two groups Group A using single File rotary and group B manual K file system. Time will be recorded in each procedure and each patient will receive stainless steel crown. Follow up for the patients will be done clinical and radiographical success will be seen, postoperative pain will be measured and all data will be collected and statistically analyzed.

Eligibility Criteria:
Inclusion Criteria:

1. Absence of external or internal root resorption
2. presence of two thirds of the root
3. Primary molars with deep caries and irreversible pulpitis that require pulpectomy in a single visit. Molars can be vital with a history of spontaneous pain or non-vital as indicated by absence of bleeding from the pulp.

Exclusion Criteria:

* Children with physical, intellectual disability or medical conditions that may complicate treatment.
* Teeth with poor prognosis due to the presence of a sinus, excessive mobility or advanced bone resorption.
* Teeth with radiolucent areas in furcation regions.
Effectivness of Tramadol or Topic Lidocaine on Postoperative Analgesia in Laparoscopic Colorectal Resection.

Comparison of different postoperative analgesia after laparoscopic colorectal surgery

Postoperative pain treatment should be multimodal and opioid sparing. Thoracic epidural analgesia could relieve pain after laparoscopic surgery. Although ERAS guidelines suggest to use less invasive pain relieve technique, opioids are widely used perioperatively, despite of their side effects. Non-opioids and 5% lidocaine patches, used topicaly, could effectively reduce opioid consumption and their side effects.

Namely, efficient perioperative pain treatment is important to prevent late neuropathic pain, also after laparoscopic lower abdominal surgery. Its incidence is usually low compared to open surgery.

The aim of present study was to evaluate, if opioid consumption in laparoscopic colorectal surgery could be reduced with lidocaine patch at the wound site or with infusion of metamizole and tramadol and if the results meets epidural analgesia. We also compared the incidence of postoperative neuropathic pain among groups.

Prospective, randomised trial with 4 parallel groups was conducted at the University medical centre (UMC) Ljubljana. ASA (American Society of Anaesthesiologists) Class 2-3 high risk surgical patients from the Clinical department of abdominal surgery were included in the study. Adult patients that underwent laparoscopic colorectal surgery were included.

Eligibility Criteria:
Inclusion Criteria:

* scheduled elective laparoscopic colorectal surgery

Exclusion Criteria:

* critical preoperative state, pregnant women, laparotomy and palliative procedures.
Extracorporal Cytokin Removal in Septic Shock: a Prospective, Randomized, Multicenter Clinical Trial

Sepsis and septic shock have mortality rates between 20-50%. When standard therapeutic measures fail to improve patients' condition, additional therapeutic alternatives are applied to reduce morbidity and mortality. One of the most recent alternatives is extracorporeal cytokine hemoadsorption. One of the most tested devices is CytoSorb, however, there are a lot of open questions, such timing, dosing and of course its overall efficacy. This study aims to compare the efficacy of standard medical therapy (Group A, SMT) and continuous extracorporeal cytokine removal with CytoSorb therapy in patients with early refractory septic shock. Furthermore, we compare the dosing of CytoSorb adsorber device - as the cartridge will be changed in every (12 Group B) or 24 hours (Group C).


Eligibility Criteria:
Inclusion Criteria:

* Septic shock as defined by the Sepsis-3 criteria
* Septic shock both medical or surgical ethiology (except for re-operation)
* APACHE \> 25
* Mechanical ventilation
* Norepinephrine requirement ≥0.4 µg/kg/min for at least 30 minutes, when hypovolemia is highly unlikely as indicated by invasive hemodynamic measurements assessed by the attending physician
* Invasive hemodynamic monitoring to determine cardiac output and derived variables
* Procalcitonin level ≥ 10 ng/ml
* Inclusion within 6 - 24 hours after the onset of vasopressor need and after all standard therapeutic measures have been implemented without clinical improvement (i.e.: the shock is considered refractory)

Exclusion Criteria:

* Patients under 18 years and over 80
* Lack of health insurance
* Pregnancy
* Standard guideline-based medical treatment not exhausted (detailed below at 3.6) standard medical therapy)
* End stage organ failure
* New York Heart Association Class IV.
* Chronic renal failure with eGFR \< 15 ml/min/1,73 m2
* End-stage liver disease (MELD score \>30, Child-Pugh score Class C
* Unlikely survival for 24 hours according to the attending physician
* Acute onset of hemato-oncological illness
* Post cardiopulmonary resuscitation care
* Re-operation in context with the septic insult
* Immunosuppression
* systemic steroid therapy (\>10 mg prednisolon/day)
* immunosuppressive agents (i.e.: methotrexate, azathioprine, cyclosporin, tacrolimus, cyclophosphamide)
* Human immunodeficiency virus infection (active AIDS): HIV-VL \> 50 copies/mL
* Patients with transplanted vital organs
* Thrombocytopenia (\<20.000/ml)
* More than 10%-of body surface area with a third-degree burn
* Acute coronary syndrome
Hysteroscopic Bubble Suction Test and Tubal Peristalsis (Darwish Test) in Hydrosalpnix

Tubal patency testing is essential for infertility evaluation. Standard tests are hysterosalpingography and laparoscopic perchromation test. In 2016, a hysteroscopic bubble suction test was described in apparently normal tubes. However, the efficacy of bubble suction test in abnormal tubes like hydrosalpnix has not been studied.

Nowadays, hysteroscopy is extensively used for fertility assessment. In a previous study, it is recommended to add hysteroscopy to the routine infertility work-up to achieve a better assessment of infertility cases.

In 2016, hysteroscopy as a predictor test of tubal patency and tubal peristalsis was introduced. It is concluded that hysteroscopic bubble suction test is a good initial screening test for tubal patency nearly comparable to HSG and DL. It should be attempted in every case of OH prior to referral for more invasive HSG or laparoscopic chromopertubation test.

Thereafter, some authors tried the same idea of bubble suction test and were over-enthusiastic with this test and considered it superior to hysterosalpingography (HSG) in detection of tubal patency in infertile women. They wrongly described HSG as a historic tool despite being recommended as a basic infertility test by many organizations. Some authors criticized the results of these studies and underestimated their clinical implication. One of the objections were lack of differentiation between normal tubes and damaged or narrowed but still patent tubes.

Aim of the work:

To test whether bubble suction test and osteal peristalsis are preserved or lost in cases with hydrosalpnix.

Design: A prospective double blinded randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* Infertility patients scheduled for combined laparoscopy and hysteroscopy

Exclusion Criteria:

* No HSG
Measurement of Echogenic Area in the Border of the Fetal Ventricles

Sonographic coronal section in the lateral fetal ventricles shows echogenic area in the ventricles borders creating an "halo" around the ventricles. Histologically this area correlates to the Stratified transitional field. In this study we would like to measure this area for the purpose of creating a nomogram.


Eligibility Criteria:
Inclusion Criteria:

* pregnant women 22-37 GA
* well dated pregnancy
* singleton pregnancy

Exclusion Criteria:

* no first trimester dating
* multifetal pregnancy
* known CNS abnormalities in the fetus
* small for gestational age
Optimal Regimen of Patient-controlled Epidural Analgesia in Laboring Patients

To test the efficacy of different recipes of epidural infusions used for providing pain relief during labor in parturients.

In this prospective trial, the investigators would like to examine the efficacy of several different PCEA protocols in 250 parturients who receive CSE for labor pain. Any patient with failed epidural, delivery within 2 hours of epidural insertion, or Cesarean section will be excluded from the study. Each patient will be assigned to one of five groups (A - E), depending on the day of admission for delivery, excluding Friday and Saturday (observed religious holidays). Each group will have 50 patients.

Eligibility Criteria:
Inclusion Criteria:

Parturients receiving Combined Spinal epidural analgesia for labor pain relief.

Exclusion Criteria:

Any patient with failed epidural, delivery within 2 hours of epidural insertion, or Cesarean section will be excluded from the study.